A drug targeting the KRAS mutation nearly doubles survival time for advanced pancreatic cancer patients — one of the biggest shifts in years. Plus, Paducah's FreedomFest turns five and the EU backs a €75M clean energy investment.
Audio is available on Spreaker — see link below.
A drug called daraxonrasib has just delivered phase three trial results that nearly double survival time for people with advanced pancreatic cancer. That's not incremental progress.
Shifting to something warmer now. The city of Paducah, Kentucky is marking its fifth annual Juneteenth celebration this year, now rebranded as FreedomFest.
And on the energy front, the European Investment Bank has signed a seventy-five million euro loan with Ingeteam, a Spanish renewable energy company, to fund research and development in clean energy and electrification technologies. The key point here is not just the money.
Chapter summary auto-generated from the verified script. Listen to the full episode for the complete content.